Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Summary

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Bipolar I Disorder

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

LB Pharmaceuticals Inc.

Last updated on ClinicalTrials.gov

July 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites